Sort by
Refine Your Search
-
Listed
-
Category
-
Country
-
Program
-
Field
-
University of North Carolina at Chapel Hill | Chapel Hill, North Carolina | United States | 1 day ago
disorders, including clinical trials to test new forms of intravenous enzyme replacement therapy as well as alternative therapies, such as gene therapy and intrathecal drug delivery. The candidate will join
-
and the obesity-increased risk in multiple types of cancer, the Holden Comprehensive Cancer (HCCC) at the Carver College of Medicine, University of Iowa (https://cancer.uiowa.edu/) recently established
-
Director of Training may act on behalf of the Director. The AD also provides direct clinical services such as individual therapy, group therapy, psychological assessment, crisis intervention, educational
-
patient care. About the Center: The Center for Hematopoiesis and Hemoglobinopathies Research will focus on developing innovative therapies for sickle cell disease, thalassemia, and other inherited disorders
-
Responsibilities will include developing next-generation genome engineering technologies for gene and cell therapy applications as well as functional genomics. In particular, you will focus on delivery methods
-
therapy. However, the precise characterisation of a CAF, its properties compared to normal (non-cancer-associated) fibroblasts, and the underlying mechanisms for transformation of normal fibroblasts
-
able to multi-task; demonstrated ability to work as part of a team, as well as independently; knowledge of IRB and human research protection regulations; prior experience in gene therapy trials preferred
-
require the use of cell lines and mouse models to mechanistically determine how tumor-intrinsic and systemic metabolism impacts cancer therapy. The individual will also be expected to be excited and
-
(hepatic differentiation of stem cells, targeting of hematopoietic stem cells - gene therapy, somite and limb patterning, etc.). Course organisation The Molecular Medicine MD/PhD programme is three to four
-
, heart valve disease (structural), heart failure (advanced cardiac therapies), heart rhythm disorders (arrhythmias), and risk factor reduction. Together our team of physicians, nurse practitioners